1. Scrip
  2. >>R&D

COVID-19 Vaccines For Kids: Don’t Forget The Rotavirus Experience

Current Data Very Limited

 
• By Anju Ghangurde

An ex-member of the strategic advisory group to WHO's Global Vaccine Safety Initiative and infectious diseases expert shares his views on COVID-19 vaccines, shaping pediatric trials and areas that may need attention.

School child wearing face mask during corona virus and flu outbreak. Boy and girl going back to school after covid-19 quarantine and lockdown. Group of kids in masks for coronavirus prevention.
Expert Outlines Views On COVID-19 Vaccine Studies For Children • Source: Shutterstock

As COVID-19 vaccinations for adults begin to get underway in some countries, expert opinion appears varied on how soon children of different age groups should be enrolled in research trials for these immunization shots.

The American Academy of Pediatrics last month emphasized the need to include children at the earliest possible stage to reduce delays in giving them access to life-saving vaccines, while some members of the US Food and Drug Administration’s Vaccines and Related Biologics Advisory Committee on coronavirus vaccines had earlier stressed the need for a “very solid” database pertaining to the safety of such vaccines in older adults, before pushing ahead with pediatric enrollment in trials

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.